ClinicalTrials.gg
CompletedNCT07866664Updated Oct 8, 2026

Association Between Periodontal Status and the Interrupted Supportive Periodontal Therapy During the COVID-19 Pandemic

An observational study in Compliance, Periodontitis and Periodontal Therapy, sponsored by University of Zagreb. Completed at 1 site in Croatia. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Zagreb · Observational

Updated Oct 8, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
60
Sex
All
01

Study summary

This cross-sectional observational study compared the clinical periodontal status and oral health-related quality of life between patients who continued regular supportive periodontal therapy (SPT) visits during the COVID-19 pandemic and those who experienced a prolonged interruption of SPT. The study included patients who had completed active periodontal therapy and were enrolled in an SPT program, divided into a non-compliant group with prolonged SPT interruption and a compliant group with regular SPT. Clinical periodontal parameters including plaque index, bleeding on probing, probing depth, gingival recession, clinical attachment level, and distribution of probing depths were assessed. Oral health-related quality of life was evaluated using the OHIP-14 questionnaire.

02

Conditions studied

  • Compliance
  • Periodontitis
  • Periodontal Therapy
03

In context

Patient Compliance

131 studies on the registry are indexed under Patient Compliance; 40 are open to participants now.

This study's enrollment of 60 is below the median of 200 across 31 observational studies indexed under Patient Compliance.

Browse Patient Compliance studies →

Lead sponsor

University of Zagreb is the lead sponsor of 71 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients who had completed active periodontal therapy and were enrolled in a supportive periodontal therapy (SPT) program, divided into those who continued regular SPT visits during the COVID-19 pandemic and those who experienced a prolonged interruption of SPT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a minimum of 20 teeth in the oral cavity (third molars excluded)
  • diagnosed stage III or IV periodontitis according to the 2017 classification
  • completed active periodontal therapy two years before the onset of the COVID-19 pandemic
  • enrollment in a supportive periodontal therapy program

Exclusion criteria

Exclusion Criteria:

  • no active periodontal therapy performed before the onset of the pandemic
  • use of systemic antibiotics in the last 6 months
  • pregnancy
  • breastfeeding
  • alcohol or drugs abuse
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • Compliant
  • Non-compliant

    Other: Prolonged interruption of supportive periodontal therapy (≥24 months)

Interventions

  • OtherProlonged interruption of supportive periodontal therapy (≥24 months)

    Observational comparison of patients who experienced a prolonged interruption of supportive periodontal therapy during the COVID-19 pandemic versus those who continued regular SPT visits. No treatment is assigned by the investigator; participants are observed based on their existing SPT compliance status.

06

What researchers measure

Primary outcomes

  1. PPD

    Periodontal probing depth - the distance in millimeters from the gingival margin to the base of the periodontal pocket. It is measured using a standard periodontal probe at 6 sites per tooth. Higher values indicate deeper periodontal pockets (worse periodontal status), while lower values indicate shallower pockets (better periodontal status).

    Time frame: Baseline (single assessment)

Secondary outcomes

  1. OHIP-14

    OHIP-14 is a 14-item questionnaire that assesses the impact of oral health on oral health-related quality of life. Each item is scored on a Likert scale from 0 to 4 (0 = never, 1 = hardly ever, 2 = occasionally, 3 = fairly often, 4 = very often). The total score ranges from 0 to 56. Higher scores indicate worse oral health-related quality of life, while lower scores indicate better oral health-related quality of life.

    Time frame: Baseline (single assessment)

Other outcomes

  1. RE

    Gingival recession is the distance in millimeters from the cementoenamel junction to the gingival margin. It is measured using a standard periodontal probe. Higher values indicate more pronounced gingival recession (worse condition), while lower values or a value of 0 indicate a normal position of the gingival margin.

    Time frame: Baseline (single assessment)

  2. CAL

    Clinical attachment level is the sum of probing depth and gingival recession at a given tooth site, expressed in millimeters. It represents the distance from the cementoenamel junction to the base of the periodontal pocket. Higher values indicate greater clinical attachment loss (worse condition), while lower values indicate a more preserved periodontal supporting structures.

    Time frame: Baseline (single assessment)

  3. FMPS

    Full-mouth plaque score - plaque accumulation will be assessing the presence or absence of supragingival plaque on six surfaces of each tooth. The results will be expressed as the percentage of plaque-positive surfaces relative to the total number of examined surfaces. FMPS is calculated by dividing the number of sites with plaque by the total number of examined sites and multiplying by 100. Scores range from 0% to 100%. Higher percentages indicate greater plaque accumulation (worse condition), while lower percentages indicate better oral hygiene.

    Time frame: Baseline (single assessment)

  4. FMBS

    Full-mouth bleeding score - gingival inflammation will be assessed recorded dichotomously (presence/absence of bleeding) following gentle probing of the gingival sulcus at standardized sites. The outcome will be expressed as the percentage of bleeding-positive sites, reflecting the degree of gingival inflammatory response. FMBS is calculated by dividing the number of bleeding sites by the total number of examined sites and multiplying by 100. Scores range from 0% to 100%. Higher percentages indicate greater gingival inflammation (worse condition), while lower percentages indicate healthier gingival tissue.

    Time frame: Baseline (single assessment)

07

Study locations

1 site
  • Stomatološka poliklinika Zagreb
    Zagreb, City of Zagreb 10000, Croatia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866664
Lead sponsor
University of Zagreb
Responsible party
Ivana Bradvica (Principal Investigator, University of Zagreb) — Principal investigator
First posted
Oct 8, 2026
Start date
Jan 7, 2023
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion